secwatch.observer — SEC 8-K summary
======================================

Issuer:     FRACTYL HEALTH, INC. (GUTS)
CIK:        0001572616
Form:       8-K
Filed at:   2026-02-26T23:59:59+00:00
Accession:  0001193125-26-073374
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fractyl Health completes randomization in REMAIN-1 pivotal trial for Revita; topline data expected early Q4 2026
--------------------------------------------------------------------------------

- Randomization completed in double-blind, sham-controlled REMAIN-1 study for Revita in weight maintenance after GLP-1 therapy discontinuation.
- Topline 6-month pivotal data expected early Q4 2026; potential FDA marketing submission late Q4 2026.
- Cash runway reiterated into early 2027, beyond pivotal readout.
- Anticipated milestones: Q2 2026 FDA feedback on De Novo pathway, 1-year data from REVEAL-1 and REMAIN-1 Midpoint Cohort.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1572616/000119312526073374/0001193125-26-073374-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1572616/000119312526073374/guts-20260226.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-073374

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer